CK226: A novel surface molecule involved in human T cell activation

Research output: Contribution to journalArticle

Abstract

In this report we describe a novel surface molecule, termed CK226, which mediates activation of human T lymphocytes. This molecule was identified by the monoclonal antibody (mAb) CK226 that had been raised against the human leukemic T cell line CEM/K. The CK226 mAb reacted with 10%-35% of human peripheral blood lymphocytes, virtually all monocytes, polymorphonuclear leukocytes and large granular lymphocytes. As demonstrated by two-color cytofluorimetric analysis, the majority of CK226+ lymphocytes were CD3+, whereas a minority coexpressed surface immunoglobulins. Biochemical analysis showed that the surface molecules immunoprecipitated by CK226 mAb from lysates of 125I surface-labeled cloned T lymphocytes were represented by two distinct polypeptides. Their apparent molecular mass was 160 kDa and 80 kDa under nonreducing conditions and 75 kDa and 80 kDa under reducing conditions. CK226 mAb induced proliferation of peripheral blood lymphocytes and interleukin 2 release. Cell proliferation was optimal in the presence of submitogenic doses of phorbol 12-myristate 13-acetate. Finally all T cell clones analyzed for their responsiveness to CK226 mAb released interleukin 2 in the presence of the antibody, regardless of their CD4+ or CD8+ phenotype. Antibody-induced modulation of CD3/T cell receptor molecules inhibited further responses of cloned cells to CK226 mAb. Thus, we conclude that CK226 mAb defines a novel surface molecule which initiates an alternative pathway of T cell activation in humans.

Original languageEnglish
Pages (from-to)2069-2074
Number of pages6
JournalEuropean Journal of Immunology
Volume19
Issue number11
DOIs
Publication statusPublished - 1989

Fingerprint

Monoclonal Antibodies
T-Lymphocytes
Lymphocytes
Interleukin-2
B-Cell Antigen Receptors
Antibodies
T-Cell Antigen Receptor
Monocytes
Acetates
Neutrophils
Clone Cells
Color
Cell Proliferation
Phenotype
Cell Line
Peptides

ASJC Scopus subject areas

  • Immunology

Cite this

CK226 : A novel surface molecule involved in human T cell activation. / Poggi, A.; Raffaella Zocchi, M.; Moretta, L.; Moretta, A.

In: European Journal of Immunology, Vol. 19, No. 11, 1989, p. 2069-2074.

Research output: Contribution to journalArticle

@article{b6a99e30951f417fb773f62b8149e27a,
title = "CK226: A novel surface molecule involved in human T cell activation",
abstract = "In this report we describe a novel surface molecule, termed CK226, which mediates activation of human T lymphocytes. This molecule was identified by the monoclonal antibody (mAb) CK226 that had been raised against the human leukemic T cell line CEM/K. The CK226 mAb reacted with 10{\%}-35{\%} of human peripheral blood lymphocytes, virtually all monocytes, polymorphonuclear leukocytes and large granular lymphocytes. As demonstrated by two-color cytofluorimetric analysis, the majority of CK226+ lymphocytes were CD3+, whereas a minority coexpressed surface immunoglobulins. Biochemical analysis showed that the surface molecules immunoprecipitated by CK226 mAb from lysates of 125I surface-labeled cloned T lymphocytes were represented by two distinct polypeptides. Their apparent molecular mass was 160 kDa and 80 kDa under nonreducing conditions and 75 kDa and 80 kDa under reducing conditions. CK226 mAb induced proliferation of peripheral blood lymphocytes and interleukin 2 release. Cell proliferation was optimal in the presence of submitogenic doses of phorbol 12-myristate 13-acetate. Finally all T cell clones analyzed for their responsiveness to CK226 mAb released interleukin 2 in the presence of the antibody, regardless of their CD4+ or CD8+ phenotype. Antibody-induced modulation of CD3/T cell receptor molecules inhibited further responses of cloned cells to CK226 mAb. Thus, we conclude that CK226 mAb defines a novel surface molecule which initiates an alternative pathway of T cell activation in humans.",
author = "A. Poggi and {Raffaella Zocchi}, M. and L. Moretta and A. Moretta",
year = "1989",
doi = "10.1002/eji.1830191115",
language = "English",
volume = "19",
pages = "2069--2074",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "11",

}

TY - JOUR

T1 - CK226

T2 - A novel surface molecule involved in human T cell activation

AU - Poggi, A.

AU - Raffaella Zocchi, M.

AU - Moretta, L.

AU - Moretta, A.

PY - 1989

Y1 - 1989

N2 - In this report we describe a novel surface molecule, termed CK226, which mediates activation of human T lymphocytes. This molecule was identified by the monoclonal antibody (mAb) CK226 that had been raised against the human leukemic T cell line CEM/K. The CK226 mAb reacted with 10%-35% of human peripheral blood lymphocytes, virtually all monocytes, polymorphonuclear leukocytes and large granular lymphocytes. As demonstrated by two-color cytofluorimetric analysis, the majority of CK226+ lymphocytes were CD3+, whereas a minority coexpressed surface immunoglobulins. Biochemical analysis showed that the surface molecules immunoprecipitated by CK226 mAb from lysates of 125I surface-labeled cloned T lymphocytes were represented by two distinct polypeptides. Their apparent molecular mass was 160 kDa and 80 kDa under nonreducing conditions and 75 kDa and 80 kDa under reducing conditions. CK226 mAb induced proliferation of peripheral blood lymphocytes and interleukin 2 release. Cell proliferation was optimal in the presence of submitogenic doses of phorbol 12-myristate 13-acetate. Finally all T cell clones analyzed for their responsiveness to CK226 mAb released interleukin 2 in the presence of the antibody, regardless of their CD4+ or CD8+ phenotype. Antibody-induced modulation of CD3/T cell receptor molecules inhibited further responses of cloned cells to CK226 mAb. Thus, we conclude that CK226 mAb defines a novel surface molecule which initiates an alternative pathway of T cell activation in humans.

AB - In this report we describe a novel surface molecule, termed CK226, which mediates activation of human T lymphocytes. This molecule was identified by the monoclonal antibody (mAb) CK226 that had been raised against the human leukemic T cell line CEM/K. The CK226 mAb reacted with 10%-35% of human peripheral blood lymphocytes, virtually all monocytes, polymorphonuclear leukocytes and large granular lymphocytes. As demonstrated by two-color cytofluorimetric analysis, the majority of CK226+ lymphocytes were CD3+, whereas a minority coexpressed surface immunoglobulins. Biochemical analysis showed that the surface molecules immunoprecipitated by CK226 mAb from lysates of 125I surface-labeled cloned T lymphocytes were represented by two distinct polypeptides. Their apparent molecular mass was 160 kDa and 80 kDa under nonreducing conditions and 75 kDa and 80 kDa under reducing conditions. CK226 mAb induced proliferation of peripheral blood lymphocytes and interleukin 2 release. Cell proliferation was optimal in the presence of submitogenic doses of phorbol 12-myristate 13-acetate. Finally all T cell clones analyzed for their responsiveness to CK226 mAb released interleukin 2 in the presence of the antibody, regardless of their CD4+ or CD8+ phenotype. Antibody-induced modulation of CD3/T cell receptor molecules inhibited further responses of cloned cells to CK226 mAb. Thus, we conclude that CK226 mAb defines a novel surface molecule which initiates an alternative pathway of T cell activation in humans.

UR - http://www.scopus.com/inward/record.url?scp=0024818108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024818108&partnerID=8YFLogxK

U2 - 10.1002/eji.1830191115

DO - 10.1002/eji.1830191115

M3 - Article

C2 - 2532139

AN - SCOPUS:0024818108

VL - 19

SP - 2069

EP - 2074

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 11

ER -